Single-cell mutational profiling enhances the clinical evaluation of AML MRD
Asiri Ediriwickrema(Stanford University), Ravindra Majeti(Stanford University), M. Ryan Corces(Gladstone Institutes), Alexey Aleshin(Natera (United States)), Melissa Stafford(Cancer Institute (WIA)), Thomas Köhnke(California Institute for Regenerative Medicine), Michaela Liedtke(Cancer Institute (WIA)), Johannes G. Reiter(Institute of Science and Technology Austria), Bruno C. Medeiros(Stanford Medicine)
Cited by 98
Related Papers
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
|Nature Methods|2017|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression
|Nature|2011|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis
|Nature Genetics|2021|1.5k